• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Expert Rev Vaccines . Interim seasonal influenza vaccine effectiveness estimates as proxy for final estimates: Analysis of systematically identifie

tetano

Editor, Senior Moderator
Expert Rev Vaccines


. 2021 Mar 8.
doi: 10.1080/14760584.2021.1899821. Online ahead of print.
Interim seasonal influenza vaccine effectiveness estimates as proxy for final estimates: Analysis of systematically identified matched pairs of interim/final estimates from test-negative design studies in outpatient settings from 2010/11 to 2018/19


George N Okoli[SUP] 1 2 3 [/SUP], Tiba Abdulwahid[SUP] 2 [/SUP], Florentin Racovitan[SUP] 3 [/SUP], Christiaan H Righolt[SUP] 3 4 [/SUP], Salaheddin M Mahmud[SUP] 1 3 4 [/SUP]



Affiliations

Abstract

Objectives: : Limited time for seasonal influenza vaccine development means that the World Health Organization has to consider interim (early) rather than final vaccine effectiveness (VE) estimates in deciding influenza vaccine composition. We assessed agreement between interim and final VE estimates, and factors that may determine a substantial difference (?10%) between point estimates.
Methods: : This was a mixed methods study. We systematically searched, identified and matched interim/final VE studies of test-negative design (TND) type in outpatient settings after the 2009/10 influenza pandemic. The chi-square statistic (?2) was used to assess the statistical significance of the difference between paired interim/final VE estimates. We calculated the difference between point estimates and used multivariable logistic regression to assess factors that may determine a substantial difference.
Results: We identified 68 interim/final VE pairs. There was no statistically significant difference between almost all compared pairs. An inconsistent statistical model for interim/final VE estimation and interim VE estimation before the epidemic peak increased the odds of having a substantial difference between estimates.
Conclusion: : Interim influenza VE appears to be sufficient for vaccine composition decision-making. Consistency in interim/final VE estimation, and interim VE estimation during/after epidemic peak may increase agreement between the VE estimates.

Keywords: Effectiveness; Seasonal Influenza; Systematic Review; Test-negative Design; Vaccine.
 
Back
Top Bottom